Global market- Heart Failure Drug 2017 key players, share, trend, segmentation and forecast to 2026

Heart Failure Drug Market 

ReportsMonitor has added a report on Heart Failure Drug Market.

This report offers an overview of the market trends, drivers, and barriers with respect to the Heart Failure Drug market. It also provides a detailed overview of the market of different regions across Global, Europe, China, Japan, India, Southeast Asia and Others.

If you want sample of this Report -

https://www.reportsmonitor.com/request-sample/?post=362203

Global Data estimates sales of HF medicine to be approximately $3.7B across the 7MM in 2016, encompassing the US, the five major European markets (5EU: France, Germany, Italy, Spain and UK), and Japan. By 2026, Global Data expects the HF market to grow at a strong Compound Annual Growth Rate (CAGR) of 15.7%, reaching sales of $16.1B by the end of the forecast period. Chronic HF therapeutics accounted for 95.9% of the total HF market in 2015, and despite the launch of a new acute HF therapy, this figure is expected to increase slightly to 98.7% by 2026.

Key Questions Answered

- The level of unmet needs in the HF market is significantly high. Will the pipeline drugs fulfil these unmet needs of the market? Key Opinion Leaders (KOLs) interviewed by Global Data provide insights and highlight opportunities for drug developers.

- The HF market is crowded with cheap, generic, “me-too” drugs, making it a particularly difficult market to penetrate. The current late-stage pipeline consists of several chronic HF therapies, and three novel acute HF therapies. How will the market be impacted by the launch of these drugs? Which of the marketed and

Scope

- Overview of HF, both chronic and acute, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

- Annualized HF therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the chronic and acute HF therapeutics markets.

If you want to check Discount on this Report -

https://www.reportsmonitor.com/check-discount/?post=362203

Table Of Contents

1 Table of Contents1 Table of Contents 2

1.1 List of Tables 9

1.2 List of Figures 10

2 Heart Failure: Executive Summary 12

2.1 The HF Market Will Exhibit Strong Growth Between 2016 and 2026 12

2.2 Label Expansion to HF with Preserved Ejection Fraction Will Fuel Market Growth

2.3 The HF Market Has Considerable Unmet Needs, Despite the Availability of Well-Established Therapies and a Promising Pipeline 15

2.4 Opportunities Remain for All Aspects of HF, But What the Market Really Needs Is a Transformational Therapy 16

2.5 Entresto Will Dominate the HF Market 16

2.6 What Do Physicians Think? 17

3 Introduction 20

3.1 Catalyst 20

3.2 Related Reports 20

4 Disease Overview 21

4.1 Etiology and Pathophysiology 21

4.1.1 Etiology 21

4.1.2 Pathophysiology 23

4.1.3 Biomarkers/Targets of Interest 25

4.2 Classification or Staging Systems 26

4.3 Symptoms 27

4.4 Prognosis 28

4.5 Quality of Life 29

Continue.......

Full Report Access -

https://www.reportsmonitor.com/pharmapoint-heart-failure-global-drug-forecast-and-market-analysis-to-2026/

Reports Monitor is a platform to meet the market research and business intelligence requirements. Our aim is to change the dynamics of the Market Research industry by providing quality intelligence backed by data. Your requirement for market forecasting is fulfilled by our exclusive quantitative and analytics driven intelligence. Decision makers can now rely on our distinct data gathering methods to get factual market forecasting and detailed analysis.

Address: Office C & D - 4th Floor, Siddhi Towers, Above Rupee Bank, Kondhwa Road, Pune 411048, Maharashtra, India

This release was published on openPR.